Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

Caicun Zhou, MD, PhD
Taletrectinib Under NMPA Review in China for Advanced or Metastatic ROS1+ NSCLC

November 22nd 2023

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of the next-generation ROS1 TKI taletrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer with prior exposure to a ROS1 TKI.

Bayer Recalls Oral Larotrectinib Solution Because of Microbial Contamination
Bayer Recalls Oral Larotrectinib Solution Because of Microbial Contamination

November 22nd 2023

FDA
FDA Approves Companion Diagnostic for Capivasertib Plus Fulvestrant in Advanced HR+/HER2–Breast Cancer

November 21st 2023

Amivantamab Plus Chemo in EGFR+ Advanced NSCLC Following Osimertinib Progression | Image Credit: © yodiyim - stock.adobe.com
FDA Approval Sought for Amivantamab Plus Chemo in EGFR+ Advanced NSCLC Following Osimertinib Progression

November 20th 2023

©  stock.adobe.com
CAR-M Therapy CT-0508 Shows Promise in HER2-Overexpressing Recurrent/Metastatic Solid Tumors

November 19th 2023

Video Series
Video Interviews
Podcasts

More News